AVTE:NSD-Aerovate Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 24.30

Change

-0.16 (-0.65)%

Market Cap

USD 0.61B

Volume

0.07M

Avg Analyst Target

USD 24.00 (-1.23%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AVTE Stock Forecast & Price:
Based on the Aerovate Therapeutics Inc stock forecasts from 1 analysts, the average analyst target price for Aerovate Therapeutics Inc is USD 24.00 over the next 12 months. Aerovate Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aerovate Therapeutics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Aerovate Therapeutics Inc’s stock price was USD 24.30. Aerovate Therapeutics Inc’s stock price has changed by +2.66% over the past week, +38.23% over the past month and +87.07% over the last year.

About Aerovate Therapeutics Inc (AVTE:NSD)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of im ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing AVTE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 106.11% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.11% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 86.92% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.92% 97% A+ 98% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.36% 54% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.36% 54% F 51% F
Risk Return Profile  
Volatility (Standard Deviation) 12.63% 99% A+ 79% C+
Risk Adjusted Return 18.72% 65% D 53% F
Market Capitalization 0.61B 74% C 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.57 32% F 26% F
Price / Cash Flow Ratio -22.27 92% A- 83% B
EV/EBITDA -13.36 94% A 87% B+
Management Effectiveness  
Return on Equity -36.55% 72% C- 29% F
Return on Invested Capital -28.95% 75% C 28% F
Return on Assets -22.08% 60% D- 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.42 10% F 7% F
Short Percent 9.88% 22% F 18% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.